相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion
Hitomi Sakai et al.
LUNG CANCER (2019)
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer
Clive R. Taylor et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2019)
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
Maria Bassanelli et al.
ANTICANCER RESEARCH (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments
Shota Omori et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients
Livia Rojko et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer
Yangyang Wang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.
Elizabeth Jimenez Aguilar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Jie Bai et al.
ONCOTARGET (2017)
Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients
Daichi Fujimoto et al.
SCIENTIFIC REPORTS (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Predictive relevance of PD-L1 expression combined with CD8+TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Takaaki Tokito et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
Jin Sheng et al.
SCIENTIFIC REPORTS (2016)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
分享论文
